» Articles » PMID: 25700750

Long-term Survival Benefit of Revascularization Compared with Medical Therapy in Patients with Coronary Chronic Total Occlusion and Well-developed Collateral Circulation

Overview
Publisher Elsevier
Date 2015 Feb 22
PMID 25700750
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The purpose of this study was to compare the long-term clinical outcomes of patients with chronic total occlusion (CTO) and well-developed collateral circulation treated with revascularization versus medical therapy.

Background: Little is known about the clinical outcomes and optimal treatment strategies of CTO with well-developed collateral circulation.

Methods: We screened 2,024 consecutive patients with at least 1 CTO detected on coronary angiogram. Of these, we analyzed data from 738 patients with Rentrop 3 grade collateral circulation who were treated with medical therapy alone (n = 236), coronary artery bypass grafting (n = 170) or percutaneous coronary intervention (n = 332; 80.1% successful). Patients who underwent revascularization and medical therapy (revascularization group, n = 502) were compared with those who underwent medical therapy alone (medication group, n = 236) in terms of cardiac death and major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction, and repeat revascularization.

Results: During a median follow-up duration of 42 months, multivariate analysis revealed a significantly lower incidence of cardiac death (hazard ratio [HR]: 0.29; 95% confidence interval [CI]: 0.15 to 0.58; p < 0.01) and MACE (HR: 0.32; 95% CI: 0.21 to 0.49; p < 0.01) in the revascularization group compared with the medication group. After propensity score matching, the incidence of cardiac death (HR: 0.27; 95% CI: 0.09 to 0.80; p = 0.02) and MACE (HR: 0.44; 95% CI: 0.23 to 0.82; p = 0.01) were still significantly lower in the revascularization group than in the medication group.

Conclusions: In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization may reduce the risk of cardiac mortality and MACE.

Citing Articles

Elevated systemic immune-inflammatory index predicts poor coronary collateralization in type 2 diabetic patients with chronic total occlusion.

Mao L, Wang Y, Wu Z, Ding F, Lu L, Shen W Front Cardiovasc Med. 2024; 11:1490498.

PMID: 39735863 PMC: 11672344. DOI: 10.3389/fcvm.2024.1490498.


Impact of complete revascularization on long-term clinical outcomes in patients with multi-vessel disease, including chronic total occlusion.

Yang D, Park S, Rha S, Choi S, Choi C, Choi B Heart Vessels. 2024; .

PMID: 39609270 DOI: 10.1007/s00380-024-02484-5.


Predictive value of neutrophil-to-lymphocyte ratio in coronary chronic total occlusion patients.

Li Q, Yu Y, Zhou Y, Zhao Y, Wu J, Wu Y J Geriatr Cardiol. 2024; 21(5):542-549.

PMID: 38948892 PMC: 11211907. DOI: 10.26599/1671-5411.2024.05.007.


Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis.

Zhao Y, Wang P, Zheng Z, Ma Q, Shi Y, Liu J BMC Cardiovasc Disord. 2024; 24(1):324.

PMID: 38918738 PMC: 11200994. DOI: 10.1186/s12872-024-03993-x.


Percutaneous Coronary Intervention versus Optimal Medical Therapy in Patients with Chronic Total Occlusion: A Meta-Analysis.

Macherey-Meyer S, Salem K, Heyne S, Meertens M, Finke K, Mauri V J Clin Med. 2024; 13(10).

PMID: 38792462 PMC: 11122436. DOI: 10.3390/jcm13102919.